Actively Recruiting
Evaluating High-Dose Gabapentin to Reduce Opioid Use for Oral Mucositis Pain During Chemoradiation in Head and Neck Cancer
Led by Alliance for Clinical Trials in Oncology · Updated on 2026-11-04
228
Participants Needed
216
Research Sites
86 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating whether high-dose gabapentin can reduce the need for opioid pain medications in patients undergoing chemotherapy and radiation for squamous cell carcinoma of the head and neck. Oral mucositis, a painful side effect of radiation, often requires opioid treatment which can cause many side effects and long-term use concerns. This phase III trial aims to see if gabapentin can better manage mucositis pain compared to placebo. Participants are randomly assigned to receive either gabapentin or a placebo starting at the eighth radiation treatment. Both groups receive standard chemotherapy, radiation, and pain care. Gabapentin or placebo is given orally once daily on day 1, twice daily on day 2, and three times daily from day 3 onward. Treatment continues until mucositis symptoms improve and other pain medications stop, followed by a gradual dose reduction over 11 days. Blood samples are collected throughout. During the study, participants opioid use, pain levels, and quality of life are regularly assessed. Follow-up visits occur at 4 weeks, 3 months, and 6 months after chemoradiation ends. Researchers monitor pain scores, opioid use duration, adverse effects, feeding tube needs, and other health measures to understand gabapentins impact on pain and treatment outcomes.
CONDITIONS
Brief Title
High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer
Research Team
N
Nancy Garcia
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here